Favicon
Favicon

Brandon J. DeKosky

Brandon J. DeKosky, PhD

Principal Investigator


Core Member

Ragon Institute of Mass General, MIT, and Harvard

Associate Professor of Chemical Engineering

MIT

Contact


(857) 268-7214

Visit Lab Website

Efficient Engineering and Discovery of Adaptive Immune Receptors

Research Overview

Research in the DeKosky lab focuses on developing and applying new techniques to understand the B and T cell responses that make up our adaptive immune memory. These efforts have been applied to better understand immune responses in the context of viral infections, autoimmunity, and cancer. The group’s research efforts have established new high-throughput single-cell platforms to interrogate adaptive immunity and discover precise and targeted protein drugs. We seek to reveal the quantitative principles of adaptive immune protection and advance new immune-based interventions against human diseases.

Recognition and Media

Dr. DeKosky was awarded both an NIH Early Independence Award and a K99 Pathway to Independence Award (declined) in 2016 to begin his independent research laboratory. He has also received the Department of Defense Career Development Award, the Biomedical Engineering Society Rising Star Award, the AIChE Young Faculty Futures award, the Amgen Young Investigator Award, and the James S. Huston Antibody Science Talent Award. Dr. DeKosky also serves as a rotating host for the science podcast, “The Chain,” which interviews leading scientists about their careers and to discuss the latest developments in biotech and drug discovery.

About

Dr. DeKosky received a B.S. in chemical engineering from University of Kansas, and his Ph.D. in biochemical engineering at the University of Texas at Austin. His Ph.D. studies were supported by a Hertz Foundation Graduate Fellowship, an NSF Graduate Fellowship, and a Donald. D. Harrington Graduate Fellowship. Dr. DeKosky was also a postdoctoral fellow at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center near Washington, D.C., where he worked on new ways to analyze vaccine responses with a focus on major public disease health threats including HIV-1, Zika, and Ebola virus. Brandon launched his independent academic career in 2017 at the University of Kansas before joining The Ragon Institute and MIT Chemical Engineering 2021. Dr. DeKosky now works closely with researchers at The Ragon Institute, Mass General Hospital, and MIT, and he advises trainees from several affiliated academic centers including MIT Chemical Engineering, MIT Bioengineering, Harvard-MIT Health Sciences and Technology, Harvard Immunology, and Harvard Virology training programs.

Selected Publications

Antibody directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site

Banach BB, Pletnev S, Olia AS, Xu K, Zhang B, Rawi R, Bylund T, Doria-Rose N, Nguyen T-D, Fahad AF, Lee M, Lin BC, Liu T, Louder M, Madan B, McKee K, O’Dell S, Sastry M, Schön A, Bui N, Shen C-S, Wolfe JR, Chuang G-Y, Mascola JR, Kwong PD*, DeKosky BJ*,

Nature Communications, 14:7593, 2023

Immortalization and Functional Screening of Natively Paired Human T Cell Receptor Repertoires

Ahmed S. Fahad*, Cheng Yu Chung*, Sheila N. Lopez Acevedo, Nicoleen Boyle, Bharat Madan, Matias F. Gutiérrez-González, Rodrigo Matus-Nicodemos, Amy D. Laflin, Rukmini R. Ladi, John Zhou, Shauna Moore, Jacy Wolfe, Daniel C. Douek, Sian Llewellyn-Lacey, Henry H. Balfour Jr., David A. Price, Brandon J. DeKosky

Protein Engineering, Design, and Selection, 35, (2022)

Mutational Fitness Landscapes of a Broadly Neutralizing Fusion Peptide-Directed Antibody Reveal Multiple Pathways to Improve HIV-1 Neutralization

Bharat Madan*, Baoshan Zhang*, Kai Xu, Jacy Wolfe, Ahmed Fahad, Cara W. Chao, Gwo-Yu Chuang, Hui Geng, Rui Kong, Mark K. Louder, Sijy O’Dell, Reda Rawi, Rajanu Fnu, Tongqing Zhou, Thuy-Duong Nguyen, Arne Schon, Zizhang Sheng, Bob Lin, Nicole A. Doria-Rose, Lawrence Shapiro, Peter D. Kwong, Brandon J. DeKosky

Proceedings of the National Academy of Sciences of the USA, 118 (10) e2011653118, 2021. PubMed Read on Journal Site

Antibody-dependent Enhancement and SARS-CoV-2 Vaccines and Therapies

Wen Shi Lee, Adam K. Wheatley, Stephen J. Kent*, Brandon J. DeKosky*

Nature Microbiology, 5: 1185–1191, 2020. PubMed Read on Journal Site

A molecular trap against COVID-19

DeKosky BJ

Science, 369(6508): 1167-1168, 2020. PubMed Read on Journal Site

Functional Interrogation and Mining of Natively-Paired VH:VL Human Antibody Repertoires

Wang B*, DeKosky BJ*, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong W-P, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors MR, Douek DC, Sullivan NJ, Ellington AD, Mascola JR**, Georgiou G**

Nature Biotechnology, 36: 152–155, 2018. PubMed Read on Journal Site

In-depth determination and analysis of the human paired heavy and light chain antibody repertoire

DeKosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, Georgiou G

Nature Medicine, 21(1): 86-91, 2015. PubMed Read on Journal Site

High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire

DeKosky BJ, Ippolito GC, Deschner RP, Lavinder JJ, Wine Y, Rawlings BM, Varadarajan N, Giesecke C, Dörner T, Andrews SF, Wilson PC, Hunicke-Smith SP, Willson CG, Ellington AD, Georgiou G

Nature Biotechnology, 31(2): 166-169, 2013. PubMed Read on Journal Site

Explore More

Global Infectious Diseases

Though the Ragon Institute started by studying HIV, we quickly expanded to other global infectious diseases.

HIV

The study of HIV, a devastating epidemic affecting millions of people around the globe, was the Ragon Institute’s initial research program.

Vaccine Development

The best treatment for infectious diseases is prevention through effective vaccines.